**Electronic Supplementary Material**

**Development of a Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation**

Zhichao Yin¹ • Yuanyuan Wu¹ • Rui Zhu¹ • Longfa Xu¹ • Yu Lin¹ • Hongwei Yang¹ • Wenkun Fu¹ • Qiongzi Huang¹ • Dongqing Zhang¹ • Jue Wang¹ • Wei Wang¹ • Yingbin Wang¹*² • Tong Cheng¹*² • Ningshao Xia¹

¹. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, China

Supporting information to DOI: 10.1007/s12250-021-00444-1

---

**Fig. S1** CVB1 Conn-5 strain infection in mice resulted in dose-dependent mortality. One-day-old BALB/c mice were inoculated i.p. with CVB1 Conn-5 strain at a dose ranging from $10^0$ to $10^2$ TCID₅₀/ mouse (10-fold serially diluted). The control mice were mock-infected with an equal volume of medium via the same route. CVB1, Coxsackievirus B1; TCID₅₀, median tissue culture infective dose; i.p., intraperitoneally.

---

www.virosin.org
Fig. S2 The treatment of mAb 6H5 at different times after infection with CVB1. A–C The neonatal mice were challenged with lethal doses of CVB1 204 strain (10 TCID$_{50}$ per mouse). Then, the mAb 6H5 was injected i.p. at dose of 0.1 μg/g in 100 μL PBS at 24, 48 or 72 hours post-infection (n = 5–8 per group). The control group was injected with the same volume of PBS only. The mortality (A), body weight (B), and clinical symptoms (C) of all mice were monitored daily until 20 dpi. Data were shown as mean ± SEM in (B) and (C). CVB1, Coxsackievirus B1; TCID$_{50}$, median tissue culture infective dose; mAb, monoclonal antibody; i.p., intraperitoneally.